A retrospective study of transition from parenteral prostanoid to inhaled treprostinil in patients with pulmonary arterial hypertension
Latest Information Update: 15 Jun 2021
Price :
$35 *
At a glance
- Drugs Treprostinil (Primary) ; Treprostinil (Primary) ; Treprostinil (Primary) ; Epoprostenol
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- 15 Jun 2021 New trial record